Effect of gamma-vinyl GABA in tardive dyskinesia

Søren Korsgaard, Daniel E. Casey, Jes Gerlach

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

Original languageEnglish (US)
Pages (from-to)261-269
Number of pages9
JournalPsychiatry Research
Issue number4
StatePublished - Apr 1983


  • parkinsonism
  • tardive dyskinesia
  • γ-Vinyl GABA

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Effect of gamma-vinyl GABA in tardive dyskinesia'. Together they form a unique fingerprint.

Cite this